Spinal N-methyl-D-aspartate receptor 2B subunit (NR2B)-increased expression plays an important role in the facilitation and maintenance of the persistent pain state due to peripheral nerve injury. A vaccination strategy to reduce the expression of brain protein is feasible and may have therapeutic potential for neurological disorders. Thus, we investigated the effect of oral immunization with recombinant adenovirus serotype 5-mediated NR2B gene transfer (rAd5/ NR2B) for the modulation of neuropathic pain. After peroral administration of the rAd5/NR2B vaccine, transgene NR2B expression persisted for at least a week and was associated with the induction of high serum titers of NR2B-specific antibodies. Following the occurrence of mechanical allodynia due to peripheral nerve injury, NR2B-specific antibodies could pass the blood-brain barrier, transport and subsequently bind to the spinal NR2B protein. The humoral immunoresponse results in the strong antiallodynia in the spared nerve injury animal model. These data proved the feasibility of oral immunization with rAd5/NR2B for the prevention of neuropathic pain.
Introduction
Peripheral nerve injury may result in neuropathic pain due to abnormal activity in peripheral afferents and a sustained input to the spinal cord that leads to alterations in the activity and excitability of spinal cord neurons. 1, 2 Spinal glutamate receptors play an important role in the facilitation and maintenance of neuropathic pain. 3, 4 Recently, attention has been focused on N-methyl-Daspartate receptors antagonism for the treatment of neuropathic pain, which have been reported to produce symptomatic relief in a number of neuropathies. [5] [6] [7] However, these agents also induce unacceptable side effects at analgesic doses, which limit their clinical utility.
Molecular cloning has revealed three receptor subunit families (NMDAR1 (NR1), NR2 and NR3), which form hetero-oligomeric complexes in native N-methyl-D-aspartate receptor channels. 8, 9 NR1 subunits are ubiquitously expressed in the central nervous system, but the localization of N-methyl-D-aspartate receptor 2B subunit (NR2B) is more restricted and NR2B protein is found in the spinal cord, where it is localized predominantly in the superficial dorsal horn. 10, 11 Intrathecal injection of small interfering RNAs (siRNAs) targeting the NR2B subunit not only decreased the expression of NR2B protein but also abolished formalin-induced pain behaviors in a rat model. 12 Therefore, the decreased expression of the spinal NR2B protein holds promise for the treatment of neuropathic pain.
A vaccination strategy to reduce the overexpression of the brain protein is feasible and may have therapeutic potential for neurological disorders. 13 Schenk et al. 14 have reported that repeated immunization with amyloid-b attenuated Alzheimer's disease-like pathology in the PDAPP mouse model, possibly mediated via an antibody facilitating the clearance of plaques. 14 During et al. 13 demonstrated that immunized rats with an oral vaccine encoding NR1 generated autoantibodies against NR1 to produce strong antiepileptic and neuroprotective activity. Therefore, the aim of the present study was to investigate the role of oral immunization with recombinant adenovirus serotype 5-mediated NR2B gene transfer (rAd5/NR2B) for the prevention of neuropathic pain.
Results

Expression of transgene NR2B in intestinal M cells after oral immunization
To transduce gut lamina propria cells, rAd5/NR2B (10 8 plaque forming unit (PFU)) was administered via an orogastric tube into the stomachs of a group of rats, with a control group receiving a similar dose of rAd5/ EGFP. In rats treated with the oral rAd5/NR2B vector, transduction of intestinal M cells was confirmed by PCR amplification of a portion of the cytomegalovirus promoter from genomic DNA isolated from the proximal intestine. Similarly, the PCR product was also detected in rAd5/EGFP-immunized rat but not in DNA from the intestine of naive rats ( Figure 1a ). NR2B mRNA in the intestine was detected by reverse transcriptase-PCR with NR2B subunit primer sequence at 1 week after peroral dosing. The PCR product was detected only in rAd5/ NR2B-immunized rat intestine but not in the intestine of rAd5/EGFP-immunized rats or naive rats (Figure 1b ).
Time course of NR2B-specific antibody in the sera of rats following rAd5/NR2B oral vaccination
To determine the titers of the NR2B-specific antibody in rats immunized with rAd5/NR2B, an enzyme-linked immunosorbent assay was performed. After the primary vaccination with rAd5/NR2B, NR2B-specific antibodies were detected in all of the rats and the mean titer was about 5.571.9 mg ml
À1
. The titers were markedly boosted by the second vaccination. The titers of NR2B-specific antibody in sera peaked on day 28 after initial immunization and persisted over the 70-day evaluation period. In contrast, no NR2B-specific antibody was detected in sera from rAd5/EGFP-immunized rats or naive rats ( Figure 2 ).
Experimental mechanical allodynia
At about 1 month following the initial vaccination, the spared nerve injury (SNI) model of rats was used to determine the potential preventive effect of neuropathic pain of rAd5/NR2B vaccination. The SNI animals were placed on an elevated wire grid and the plantar surface of the paw stimulated with a series of ascending force von Frey monofilaments. The mechanical withdrawal threshold (MWT) was taken as the lowest force that evoked a brisk withdrawal response to one of the repetitive stimuli. All the SNI animals developed qualitative signs indicative of a marked sensory hypersensitivity of the hindpaw ipsilateral to the nerve injury after surgery. However, at 1 week after surgery, MWT of rAd5/NR2B-vaccinated rats were significantly higher than that of rAd5/EGFPvaccinated rats or naive rats (Po0.05), continued for as long as the animals were monitored (Figure 3 ). 8 PFU of rAd5/NR2B. Sera titers of NR2B-specific antibody were determined by enzyme-linked immunosorbent assay. Each value is the mean antibody titer derived from five rats. The booster immunization was performed by day 14 following the initial immunization. Higher titers of NR2B-specific antibody were induced in rats immunized with rAd5/NR2B, not detected in rats of rAd5/EGFP or naive rats. rAd5/NR2B, recombinant adenovirus serotype 5-mediated NR2B; NR2B, N-methyl-D-aspartate receptor 2B subunit. Figure 3 Changes in mechanical withdrawal threshold (MWT) to stimulation of the plantar surface of the paw after SNI. The SNI rats developed a marked mechanical hypersensitivity on the lateral surface of the paw ipsilateral to the nerve injury after surgery. MWT of the dorsal skin has a higher threshold in rats immunized with rAd5/NR2B compared with rAd5/EGFP or naive rats during the 6-week evaluation period. # Po0.05 vs presurgery; *Po0.05 vs rAd5/NR2B or naive rats. MWT, mechanical withdrawal threshold; NR2B, N-methyl-D-aspartate receptor 2B subunit; rAd5/NR2B, recombinant adenovirus serotype 5-mediated NR2B; SNI, spared nerve injury.
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Locomotor activity of the immunized animals
The locomotor activity of the immunized animals was measured using perspex boxes (230 Â 280 Â 210 mm) equipped with two parallel infrared beams, one at each end of the base of the cage. During the period of 42 days after surgery, the locomotor activity of rats immunized with rAd5/NR2B was indistinguishable from rAd5/EGFP or naive control animals ( Figure 4 ). In addition, abnormal behaviors were not observed in all rats.
Titers of NR2B-specific antibody in CSF
To confirm the passage of NR2B-specific antibody into the spinal cord, all vaccinated rats underwent non-traumatic sampling of cerebrospinal fluid (CSF) from the cisterna magna, on day 1 before SNI procedure and days 7 and 42 after SNI procedure. NR2B-specific antibody was not detected in the CSF of rAd5/NR2B-immunized rats before SNI procedure; however, after SNI procedure, NR2B-specific antibody was detected. In contrast, NR2B antibody was not detected in CSF from rAd5/EGFPimmunized rats or naive rats.
Immunoreactivity of sera from rats with NR2B protein in spinal dorsal horn
To determine whether NR2B-specific antibodies would bind to the spinal NR2B protein, spinal sections from a naive rat were stained with sera from rats immunized with rAd5/NR2B and rAd5/EGFP using the avidinbiotin immunoperoxidase method. Only sera from rAd5/NR2B-immunized rats reacted with NR2B protein in the spinal cord, consistent with the expressive pattern of NR2B protein as determined with a commercial NR2B polyclonal antibody ( Figure 5 ).
Expressive level of NR2B protein in the lumbar spinal cord of vaccinated rats
The L4-6 spinal cord segment of vaccinated rats were sampled at week 6 after SNI procedure. The intensity of NR2B expression in rAd5/NR2B-immunized rats was significantly less than that in rats immunized by rAd5/ EGFP or phosphate-buffered saline (PBS) (Figure 6a ). The ratios of NR2B protein to b-actin in the lumbar spinal cord of rats immunized by PBS' rAd5/EGFP or rAd5/ NR2B were 83.0, 78.9 and 28.2% at week 6 after surgery, suggesting that rAd5/NR2B vaccination significantly reduced the expression of NR2B protein in the lumbar spinal cord (Po0.05) (Figure 6b ). 
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Expressive level of NR2B protein in the hippocampus of vaccinated rats
To examine the NR2B protein levels in the hippocampus following rAd5/NR2B infection, western blotting analyses were performed. The results demonstrated that the expressive levels of NR2B protein in the hippocampus were not reduced following rAd5/NR2B infection ( Figure 7 ).
Discussion
Our present study demonstrated that after peroral administration of the rAd5/NR2B vaccine, transgene NR2B expression persisted for at least a week and was associated with the induction of high serum titers of NR2B-specific antibodies. Further, following the occurrence of mechanical allodynia due to peripheral nerve injury, NR2B-specific antibodies could pass the bloodbrain barrier (BBB), transport and subsequently bind to the spinal NR2B protein. Of particular interest, the humoral immunoresponse resulted in a strong antiallodynia in the SNI animal model. In this study, oral rAd5/NR2B immunization induced higher serum titers of NR2B-specific antibody. It is well known that many proteins within the CNS previously sequestered from the immune system via the BBB were presented to a naive immune system when ectopically expressed and then elicited a humoral immune response. 15 In the current report, the expression of NR2B gene in intestinal M cells has also induced a humoral immunoresponse to NR2B protein. Of relevance to our experiment on humoral autoimmunity against selected brain antigens is the demonstration of autoantibodies to amyloid-b and NR1 subunits. Schenk et al.
14 reported that repeated immunization with amyloid-b attenuated Alzheimer's disease-like pathology in the PDAPP mouse model, possibly mediated via antibody, facilitating the clearance of plaques. During et al. 13 demonstrated that immunized rats with an oral vaccine encoding NR1 generated autoantibodies against NR1.
To confirm whether NR2B-specific antibodies would pass into the spinal cord, NR2B-specific antibodies in CSF were detected using enzyme-linked immunosorbent assay. We were able to detect NR2B antibodies at low levels in the CSF, suggesting the disruption of BBB and NR2B antibody passage into the spinal cord. Under resting physiological conditions, high serum titers of antibodies do not pass the BBB efficiently. However, after a neuronal insult, the BBB has increased permeability to serum antibodies. 16 Of particular interest, glutamate itself has been reported to alter BBB permeability. 17 In this study, peripheral nerve injury would increase spinal extracellular glutamate and then increase spinal-blood barrier permeability locally, resulting in facilitated passage of NR2B antibodies into the spinal cord. Further, NR2B antibody would bind to the spinal NR2B protein, confirmed by immunostaining of sera from rats treated with NR2B protein in the spinal cord.
In addition to the regional distribution of NR2B in the spinal cord, it was also abundantly distributed in the hippocampus. Therefore, to determine the anatomic extent of the rAd5/NR2B vaccination effect, immunoblot analysis was performed to detect the expression of NR2B protein in these areas. The results showed that rAd5/ NR2B reduced the NR2B protein level only in the spinal dorsal horn following peripheral nerve injury and not in the hippocampus. Glutamate has been reported to alter BBB permeability. Hence, in the present study, it is more likely that peripheral nerve injury would increase spinal Prevention of neuropathic pain in an animal model G-M Wang et al extracellular glutamate locally and then increase spinalblood barrier permeability locally, resulting in a facilitated passage of the NR2B antibody and the reduction of NR2B protein in the spinal cord. In contrast, peripheral nerve injury would not increase hippocampus extracellular glutamate because hippocampus was not correlated with pain-related signal transmission, and we deservedly did not observe the reduction of NR2B protein in the hippocampus. The adenoviral approach, compared with the published siRNA approach to knock down the NR2B subunit, would be beneficial for the following reasons: first, the oral administration of adenoviral vaccine is more convenient than the intrathecal administration of siRNA; second, the selective delivery of NR2B antibody, limited both spatially to the site of injury and to the precise timing of injury, is one of the most promising features of the adenoviral approach. In contrast, the siRNA approach has no such advantages. The SNI model, as an animal model of persistent peripheral neuropathic pain, involves a lesion of two of the three terminal branches of the sciatic nerve (tibial and common peroneal nerves), leaving the remaining sural nerve intact. A major feature of the SNI model was the very marked hypersensitivity to normally innocuous mechanical stimuli. 18 In this study, MWT was used as an index to evaluate the effect of humoral immunoresponse induced by rAd5/NR2B vaccine against neuropathic pain. From day 7 to day 42 post-surgery monitored, MWT of rAd5/NR2B-immunized rats was significantly higher than that in control groups, including rAd5/ EGFP-immunized rats and naive rats. The results indicate that the rAd5/NR2B vaccine has a better effect in prevention of neuropathic pain.
NR2B subunit is widely expressed in the CNS and peripheral nervous system, affecting different neuronal populations, including the lumbar motoneurons. 19 Thus, the knockdown of NR2B subunits may influence the behavioral outcome of animals. Therefore, locomotor activity was monitored to assess nociceptive behavioral specificity. In this study, we found that locomotor activity of immunized rats was not affected by the vaccineinduced analgesic effect. This was similar to a previous study in which NR2B gene knockdown with NR2B siRNA did not affect motor coordination. 12 Boyce et al.
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also reported that the selective NR2B antagonists, including (7)-Ro 25-6981 and (7)-CP-101,606, caused no motor impairment. This indicated that the reduced reflex withdrawal in treated animals represents a specific pain-relieving effect and not a generalized reduction in activity in these animals. The clinical utility of the current drugs to treat neuropathic pain has been limited by their side effects. An analgesics vaccine that generates autoantibodies whose access to the spinal cord and analgesic activity is spatially and temporally regulated may hold promise as a prophylactic measure to treat neuropathic pain.
Materials and methods
Animal models
Male Sprague-Dawley rats weighing 200720 g were used in experiments which were conducted, with adherence to the guidelines for pain research. The rats were fed a standard laboratory diet and tap water and kept at 2371 1C with a 12 h light/dark cycle. All animal protocols were approved by the Animal Care Committee of Tongji Medical College, Wuhan, China. The SNI models were established as described previously. 18 
Amplification of rAd5/NR2B and oral immunization
The viral stocks of rAd5/NR2B were generated by the transient transfection of 293 cells and purified using CsCl ultracentrifugation gradients. 20 The final titer was 5 Â 10 11 PFU ml
À1
. Sprague-Dawley rats were orally immunized with rAd5/NR2B, rAd5/EGFP and PBS. Oral inoculation was carried out by administration of 200 ml 5% sodium bicarbonate via an orogastric into the stomach of rats and 10 min later followed by administration of 100 ml of rAd5/NR2B (1 Â 10 8 PFU), with a control group receiving a similar dose of rAd5/EGFP or PBS. For a booster immunization, re-immunization was carried out 2 weeks after the initial immunization.
Reverse transcriptase-PCR analysis for NR2B expression
To confirm the expression of NR2B gene in the intestinal M cells, a group of vaccinated rats (n ¼ 4) were killed for reverse transcriptase-PCR analysis 7 days following the initial immunization. Total RNA was isolated from the proximal intestine using the SV Total RNA Isolation System (Promega, Madison, WI, USA). First-strand cDNA templates were synthesized, as described previously, 21 and the templates were subjected to PCR amplification using sets of primers for NR2B and glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Assessment of titers of NR2B-specific antibody in sera and in CSF Enzyme-linked immunosorbent assays were carried out to determine NR2B-specific antibody titers in vaccinated rats. Bleeds were collected through the tail every 2 weeks after the initial immunization. After incubation for 3 h at 4 1C, the bleeds were centrifuged for 10 min at 1000 g. The sera were collected and stored at À70 1C. Microtiter wells were coated with NR2B peptide (10 mg ml
À1
) in 50 mM carbonate buffer pH 9.6 overnight at 4 1C and rinsed three times with washing buffer (PBS containing 0.05% Tween 20) . Microtiter wells were treated with blocking buffer (10% bovine calf serum in PBS) for 2 h at room temperature. The serum samples were diluted with PBS and added to the microtiter wells. After incubation overnight at 4 1C, the plates were washed five times with Prevention of neuropathic pain in an animal model G-M Wang et al the washing buffer and incubated for 1 h with an appropriate horseradish peroxidase-conjugated detection antibody. The detection antibodies were diluted at 1:5000 for anti-rat IgG in the blocking buffer. After washing the plates with the washing buffer, the plates were incubated with tetramethyl benzidine for 15 min and the reaction was stopped with the addition of 1 N H 2 SO 4 . Optical densities at 450 nm were determined using a microplate reader (Model 680, Finland). Anti-NR2B antibody concentration in rat sera was determined using serial dilutions of anti-NR2B IgG (Abcam, Cambridge, UK) of known concentration as a standard.
To determine passage of NR2B antibodies into the spinal cord, a group of vaccinated rats (n ¼ 4) underwent non-traumatic sampling of CSF from the cisterna magna on day 1 before the SNI procedure and at weeks 1 and 6 following the SNI procedure. The detection of NR2B-specific antibody in CSF was as noted above.
Assessment of mechanical allodynia and locomotor activity
Animals were placed on an elevated wire mesh grid of dynamic plantar aesthesiometer (Ugo Basile, Italy), and the lateral and medial plantar surfaces of the left hind paw were stimulated with filament probe by using one of a series of eight stimulus intensities (0.41, 0.70, 1.20, 2.00, 3.63, 5.50, 8.50 and 15.10 g). A brisk withdrawal response to one of the stimuli was taken as a positive response. Whenever a positive response to a stimulus occurred, the next smaller stimulus intensity was applied, and whenever a negative response occurred, the next higher force was applied. The testing continued for five more stimuli after the first change in response occurred, and the pattern of responses was converted to a 50% von Frey threshold using the technique described by Dixon. 24 If the animal showed no response to the highest stimulus intensity (15.10 g), 15.10 g was assigned to the threshold. 25 The locomotor activity of animals was measured using the method described by Boyce.
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Immunoreactivity of antisera with NR2B protein in spinal dorsal horn Naive rats were anesthetized with pentobarbital (100 mg kg À1 , intraperitoneally) and transcardially perfused with 0.1 M PBS solution (400 ml), followed by 4% paraformaldehyde in PBS. After 2 h, the spinal cords were removed and postfixed in 4% formalin in PBS for 4 h. Following postfixation, the tissue was cryoprotected with 30% sucrose overnight. Frozen sections (20 mm) were blocked with 2% normal goat serum in PBS for 2 h at room temperature, followed by overnight incubation at 4 1C in rabbit affinity-purified anti-NR2B antibody (1:200) (rabbit polyclonal to NMDAR2B, Abcam) or sera from immunized rats. Following overnight incubation, the sections were incubated with secondary antibody (1:250) (biotin-labeled anti-rat Ig, produced in goat, KPL; biotin-labeled anti-rabbit Ig, produced in goat, KPL) for 1 h at room temperature. Finally, the sections were incubated in a complex of avidin-biotin peroxidase for 1 h and then incubated with diaminobenzidine. Image analysis was performed with a Nikon eclipse E800 microscope (Nikon Instech Company, Kawasaki, Japan) coupled to an RT slider cool digital camera (Diagnostic Instruments Inc., Sterling Heights, MI, USA) and an Image Pro Plus 4 image analysis software (Media Cybernetics, Silver Spring, MD, USA).
Expressive level of NR2B protein in the lumbar spinal cord and the hippocampus of rats On day 42 after surgery, the lumbar spinal cord (L4-6) and the hippocampus was removed. Total proteins from the lumbar spinal cord segment or the hippocampus were prepared by addition of 1 ml of ice-cold solubilization buffer (150 mmol l À1 NaCl, 50 mmol l À1 Tris-HCl (pH 8.0), 5 mmol l À1 ethylenediaminetetraacetic acid and 1% Triton X-100) containing protease inhibitors (1 mmol l À1 phenylmethylsulfonyl fluoride and 5 mg ml À1 aprotinin). The tissue was homogenized. After being placed on ice for 30 min, the homogenate was centrifuged at 12 000 g for 30 min at 4 1C. The supernatant was assayed for protein content using the bicinchoninic acid assay method and stored at À20 1C until further use. Total protein (60 mg) was electrophoresed on a 6% sodium dodecylsulfate polyacrylamide gel using sample buffer, running buffer and relative molecular mass standards, as suggested by the manufacturer. After electrophoresis, the proteins were transferred to a polyvinyl derivative membrane and blocked with 5% nonfat dry milk. The primary antibody (1:200 dilution of rabbit polyclonal anti-NR2B, Abcam, England) was added for 2 h at room temperature in fresh blocking buffer. The membranes were washed for 30 min in washing buffer, at room temperature, before the secondary antibody (1:500) dilution of alkaline phosphatase-coupled goat anti-rabbit immunoglobulin G (KPL, Gaithersburg, MD, USA) was added for 1 h at room temperature in blocking buffer. The membrane was washed in washing buffer for another 30 min, and the antibodies were then revealed using western blot reagent plus. For densitometric analysis, blots were scanned and quantified with GeneSnap v6.05 software (England), and the results were expressed as a ratio of NR2B immunoreactivity to b-actin immunoreactivity.
Statistical analysis
Data are presented as mean7s.d. The results were evaluated by one-way analysis of variance, followed by the Student-Newman-Keuls test for multiple comparisons with SPSS v12.0. A P-value o0.05 was considered statistically significant.
